×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
Yahoo Finance
MONT-SAINT-GUIBERT, Belgium, April 04, 2024--Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"),...
1 month ago
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
GlobeNewswire
By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell...
3 months ago
Celyad Announces Management Change
PharmiWeb.com
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News:Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD),...
5 months ago
Celyad Oncology announces intention to terminate SEC reporting obligations
GlobeNewswire
Deregistration and the termination of the Company's duty to file reports under the Exchange Act are expected to be final and effective 90...
2 months ago
By dropping remaining CAR-T, Celyad closes clinical pipeline
Fierce Biotech
By dropping remaining 'off-the-shelf' CAR-T, Celyad closes clinical pipeline to complete R&D pivot ... Celyad Oncology has been making no secret...
16 months ago
StromaCare appoints Georges Rawadi as CEO
The Pharma Letter
Privately-held French biotech StromaCare, which is developing immunotherapies through stroma modulation, today announced the appointment of...
2 months ago
Deaths trigger pause in Celyad's allogeneic CAR-T trial
biopharma-reporter.com
Celyad Oncology has decided to voluntarily pause dosing and enrollment of patients in the CYAD-101-002 trial in order to investigate reports...
26 months ago
FDA Formalizes Celyad CAR-T Trial Hold while Risks Evaluated
BioSpace
FDA Formalizes Celyad CAR-T Trial Hold while Risks Evaluated ... On Feb. 28, Belgium-based Celyad Oncology voluntarily paused a clinical trial...
26 months ago
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
Business Wire
Cellistic will acquire Celyad Oncology's GMP grade cell therapy manufacturing capability, including the existing facility and all related...
19 months ago
Celyad plant buy to accelerate growth for Cellistic - BioProcess Insider
BioProcess International
Cellistic has agreed to buy Celyad's capabilities in Belgium to support its “rapidly growing” allogeneic iPSC manufacturing business.
19 months ago